By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: 32-2-559-9999 Fax: 32-2-559-9900



Company News
Cipla, Lupin (LUPN.BO) Make Bid for UCB SA’s $1 Billion Generics Unit 6/1/2015 6:22:27 AM
UCB SA, Neuropore to Develop Parkinson's Treatment in $480 Million Deal 1/16/2015 6:06:17 AM
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015 7:27:12 AM
UCB SA Terminates $1.53 Billion Sale Of Generic Drug Unit To Buyout Firms 12/17/2014 6:24:18 AM
Illinois-Based Akorn, Inc. (AKN) Eyes $2 Billion UCB SA Unit In Potential Tax Inversion Deal 9/12/2014 6:38:34 AM
UCB SA to Enhance Informatics Environment With Dotmatics' Vortex 8/7/2013 9:42:46 AM
Immunomedics, Inc. (IMMU) and UCB SA Announce Restructuring of Epratuzumab License Agreement for Up to $60 Million 12/28/2011 7:49:24 AM
UCB SA Release; Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures 12/5/2011 12:34:12 PM
UCB SA Pleads Guilty to Illegal Off-Label Marketing of Epilepsy Drug Keppra; to Pay $34.4 Million 6/9/2011 10:24:03 AM
UCB SA Plans EUR250M ($334M) Plant To Meet Cimzia Demand 1/3/2011 11:44:01 AM